The National Institute for Health and Care Excellence

Faster dementia diagnosis: inside UKRI's £80 million Dementia Challenge

From blood-based biomarkers to AI-powered tools, discover how 9 innovations are being tested in the NHS to speed up dementia ...
National Institute for Health and Care Excellence

Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Evidence-based recommendations on dostarlimab (Jemperli) for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.
National Institute for Health and Care Excellence

Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer

There are commercial access agreements for encorafenib and binimetinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

There is a commercial access agreement for dupilumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess@sanofi.com ...
National Institute for Health and Care Excellence

Rare diseases

This quality standard covers diagnosing, managing and treating rare diseases in children, young people and adults. It describes high-quality care in priority areas for improvement. Rare diseases are ...
National Institute for Health and Care Excellence

Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer

There are simple discount patient access schemes for amivantamab (Rybrevant) and lazertinib (Lazcluze). NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS ...
National Institute for Health and Care Excellence

Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over

There is a simple discount patient access scheme for garadacimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable

There is a simple discount patient access scheme for isatuximab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess ...
National Institute for Health and Care Excellence

Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
National Institute for Health and Care Excellence

Quality statement 7: Advice and support after stopping medicines for weight management or completing behavioural interventions

Advice and support for maintaining weight after stopping medicines for weight management or completing a behaviour change intervention can help to prevent weight regain and weight cycling. It can also ...